CYP3A4 and liver disorder: Consequently, these combined findings indicate that starting doses of CYP2D6, CYP2E1 and CYP3A4 substrates should be adjusted in patients with moderate or severe liver disease, whereas a dose reduction of CYP2C19 and CYP1A2 substrates should already be considered in milder forms of liver disease.